In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors

International Urology and Nephrology

Volumn 44, Issue 3, 2012, Pages 793-798

  Coskuner, Enis ^a   Cevik, Ibrahim ^b   Ozkan, Alp ^c   Dillioglugil, Ozdal ^c   Akdas, Atif ^d  

^a ACIBADEM UNIVERSITY   (Turkey)

^b ISTANBUL YENI YUZYIL UNIVERSITY   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

Author keywords

Bladder cancer; NMP22; TCC; Upper urinary tract tumor; Urine marker

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS UROGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINARY TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHI-SQUARE DISTRIBUTION; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84864284893     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0144-x     Document Type: Article

References (35)

1. Kitamura H, Tsukamoto T (2006) Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 11(1):28-37. doi:10.1007/s10147-006-0552-y (Pubitemid 43320324)
2. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR (1983) Superficial bladder cancer: progression and recurrence. J Urol 130(6):1083-1086 (Pubitemid 14207227)
3. Herr HW (1997) Natural history of superficial bladder tumors: 10-to 20-year follow-up of treated patients. World J Urol 15(2):84-88 (Pubitemid 127763990)
4. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death fromsuperficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13(6):1404-1408
5. Pagano F, Garbeglio A, Milani C, Bassi P, PegoraroV(1987) Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13(3):145-149 (Pubitemid 17103607)
6. Cheng L, Neumann RM, Bostwick DG (1999) Papillary urothelial neoplasms of low malignant potential. Cancer 86(10):2102-2108
7. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1): 62-67. doi:10.1097/00005392-199707000-00017 (Pubitemid 27251595)
8. Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM, Mauffette F, Faucher R, Perreault JP (1999) Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162(6):1946-1950
9. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O (1995) Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 154(6):2050-2053
10. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164(5):1768-1775
11. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-816. doi:10.1001/jama.293.7.810 (Pubitemid 40250364)
12. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud JJ (2003) Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169(3):921-924. doi:10.1097/01.ju.0000048 983.83079.4c (Pubitemid 36188123)
13. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M, Koyama A, Takahashi T (1997) Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 31(2):163-168 (Pubitemid 27101701)
14. Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R (2000) Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Anticancer Res 20(2B): 1169-1172 (Pubitemid 30240695)
15. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156(2 Pt 1):363-367 (Pubitemid 126445343)
16. Keesee SK, Briggman JV, Thill G, Wu YJ (1996) Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 6(2-3):189-214 (Pubitemid 26275307)
17. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL (1996) Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 156(4):1280-1285 (Pubitemid 26307594)
18. Rabbani F, Perrotti M, Russo P, Herr HW (2001) Uppertract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 19(1): 94-100 (Pubitemid 32063484)
19. Oldbring J, Glifberg I, Mikulowski P, Hellsten S (1989) Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. J Urol 141(6):1311-1313 (Pubitemid 19151784)
20. Kirkali Z, Tuzel E (2003) Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 47(2): 155-169 (Pubitemid 36945314)
21. Greene FL, American Joint Committee on Cancer, American Cancer Society (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 335-340
22. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The WorldHealth Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435-1448 (Pubitemid 28550639)
23. Wright MP, Jones DJ (2000) Surveillance for bladder cancer: the management of 4.8 million people. South-west Urologists. BJU Int 85(4):431-433 (Pubitemid 30142617)
24. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466-477. doi:10.1016/j.eururo.2005. 12.031
25. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95(8):588-597 (Pubitemid 36553505)
26. Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and metaanalyses. Urology 61(1):109-118 (Pubitemid 36151724)
27. Zwarthoff EC (2008) Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol 218:147-153. doi:10.1080/03008880802283953
28. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Roupret M, Shariat SF, Zlotta AR (2011) Urine markers for detection and surveillance of nonmuscle-invasive bladder cancer. Eur Urol 60(3):484-492. doi:10.1016/j.eururo.2011.05.053
29. Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45(3):304-313. doi:10.1016/j.eururo.2003.10.020 (Pubitemid 38221403)
30. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299-305. doi:10.1001/jama.295.3.299 (Pubitemid 43112958)
31. Hwang EC, Choi HS, Jung SI, Kwon DD, Park K, Ryu SB (2011) Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology 77(1):154-159. doi:10.1016/j.urology.2010.04.059
32. Ayyathurai R, Soloway MS (2011) Monitoring of the upper urinary tract in patients with bladder cancer. Indian J Urol 27(2):238-244. doi:10.4103/0970- 1591.82844
33. van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47(6):736-748. doi:10.1016/j.eururo. 2005.03.014 (Pubitemid 40745338)
34. Jovanovic M, Soldatovic I, Janjic A, Vuksanovic A, Dzamic Z, Acimovic M, Hadzi-Djokic J (2011) Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int 87(2):134-137. doi: 10.1159/000330246
35. Moonen PM, Kiemeney LA, Witjes JA (2005) Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. EurUrol 48(6):951-956. doi:10.1016/j.eururo. 2005.09.002 (Pubitemid 41641642)